SK279740B6 - Spôsob výroby - Google Patents
Spôsob výroby Download PDFInfo
- Publication number
- SK279740B6 SK279740B6 SK2409-91A SK240991A SK279740B6 SK 279740 B6 SK279740 B6 SK 279740B6 SK 240991 A SK240991 A SK 240991A SK 279740 B6 SK279740 B6 SK 279740B6
- Authority
- SK
- Slovakia
- Prior art keywords
- ifosfamide
- microcrystalline cellulose
- weight
- capsules
- parts
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 title description 4
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims abstract description 41
- 229960001101 ifosfamide Drugs 0.000 claims abstract description 40
- 239000002775 capsule Substances 0.000 claims abstract description 26
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 20
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 20
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 20
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 20
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 10
- 239000007787 solid Substances 0.000 claims abstract description 9
- 238000000576 coating method Methods 0.000 claims abstract description 5
- 239000013543 active substance Substances 0.000 claims abstract description 4
- 239000011248 coating agent Substances 0.000 claims abstract description 4
- 239000008240 homogeneous mixture Substances 0.000 claims abstract description 3
- 238000002156 mixing Methods 0.000 abstract description 3
- 239000007963 capsule composition Substances 0.000 abstract description 2
- 230000000181 anti-adherent effect Effects 0.000 abstract 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 239000007903 gelatin capsule Substances 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 210000004051 gastric juice Anatomy 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- -1 stearates Chemical compound 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- YKXCWZVUWWQSAV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O YKXCWZVUWWQSAV-BTVCFUMJSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- 239000004604 Blowing Agent Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4024683 | 1990-08-03 | ||
| SG181694A SG181694G (en) | 1990-08-03 | 1994-12-30 | Solid oral administration forms containing ifosfamide as active agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK279740B6 true SK279740B6 (sk) | 1999-03-12 |
Family
ID=25895607
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK2409-91A SK279740B6 (sk) | 1990-08-03 | 1991-08-02 | Spôsob výroby |
| SK543-98A SK279739B6 (sk) | 1990-08-03 | 1998-04-27 | Pevné ifosfamidové prípravky na orálnu aplikáciu a |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK543-98A SK279739B6 (sk) | 1990-08-03 | 1998-04-27 | Pevné ifosfamidové prípravky na orálnu aplikáciu a |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US5158776A (cs) |
| EP (1) | EP0469440B1 (cs) |
| JP (2) | JP3061898B2 (cs) |
| KR (1) | KR0177170B1 (cs) |
| CN (1) | CN1046851C (cs) |
| AR (1) | AR247484A1 (cs) |
| AT (1) | ATE110261T1 (cs) |
| AU (2) | AU643309B2 (cs) |
| BG (1) | BG60900B1 (cs) |
| CA (1) | CA2048367C (cs) |
| CZ (1) | CZ280475B6 (cs) |
| DE (2) | DE4124481A1 (cs) |
| DK (1) | DK0469440T3 (cs) |
| EG (1) | EG19690A (cs) |
| ES (1) | ES2058999T3 (cs) |
| FI (1) | FI97951C (cs) |
| HK (1) | HK15695A (cs) |
| HR (1) | HRP920575B1 (cs) |
| HU (1) | HU206268B (cs) |
| IE (1) | IE66378B1 (cs) |
| IL (1) | IL99031A (cs) |
| LT (1) | LT3528B (cs) |
| LV (1) | LV10043B (cs) |
| MC (1) | MC2274A1 (cs) |
| MX (1) | MX9100441A (cs) |
| NO (1) | NO178252C (cs) |
| NZ (1) | NZ239222A (cs) |
| PT (1) | PT98532B (cs) |
| RO (1) | RO113611B1 (cs) |
| SG (1) | SG181694G (cs) |
| SI (1) | SI9111342B (cs) |
| SK (2) | SK279740B6 (cs) |
| ZA (1) | ZA916124B (cs) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0804174A4 (en) * | 1993-07-21 | 1998-09-09 | Univ Kentucky Res Found | MULTI-CHAMBER HARD CAPSULES WITH CONTROLLED DELIVERY CHARACTERISTICS |
| ITFI970184A1 (it) * | 1997-07-30 | 1999-01-30 | Menarini Farma Ind | Composizioni farmaceutiche contenenti vitamina d e calcio,loro preparazione ed uso terapeutico |
| DE19733305A1 (de) * | 1997-08-01 | 1999-02-04 | Asta Medica Ag | Pharmazeutische Zusammensetzung enthaltend Ifosfamid und Carnitin |
| US6103297A (en) * | 1998-01-14 | 2000-08-15 | Matsushita Electronics Corporation | Method of manufacturing cathode-ray tube |
| DE19826517B4 (de) * | 1998-06-15 | 2006-03-23 | Baxter Healthcare S.A. | Verfahren zur Herstellung von Filmtabletten mit Cyclophosphamid als Wirkstoff und daraus hergestellte Cyclophosphamid-Filmtablette |
| US20040253307A1 (en) * | 2003-02-04 | 2004-12-16 | Brian Hague | Sugar-free oral transmucosal solid dosage forms and uses thereof |
| DE102005008797A1 (de) * | 2005-02-25 | 2006-09-07 | Baxter International Inc., Deerfield | Trofosfamid-haltige Filmtabletten und Verfahren zu deren Herstellung |
| CN106413706A (zh) * | 2014-01-06 | 2017-02-15 | 铁治疗控股公司 | 三麦芽酚铁的剂量方案 |
| GB201418710D0 (en) | 2014-10-21 | 2014-12-03 | Iron Therapeutics Holdings Ag | Dosage regimen |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3987204A (en) | 1972-09-15 | 1976-10-19 | Sucrest Corporation | Direct compression vehicle |
| JPS5646807A (en) * | 1979-09-27 | 1981-04-28 | Japan Atom Energy Res Inst | Production of composition of complex gradually releasing physiologically active substance |
| DE3111428A1 (de) * | 1981-03-24 | 1982-10-07 | Asta-Werke Ag, Chemische Fabrik, 4800 Bielefeld | Oxazaphosphorin-4-thio-alkansulfonsaeuren und deren neutrale salze, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen |
| US4618692A (en) * | 1981-09-03 | 1986-10-21 | Asta-Werke Aktiengesellschaft | 4-carbamoyloxy-oxazaphosphorins |
| US5019385A (en) * | 1984-11-09 | 1991-05-28 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Novel lymphopine LK 2 and pharmaceutic compositions containing same |
| EP0254902B1 (de) * | 1986-07-11 | 1991-08-28 | ASTA Pharma Aktiengesellschaft | Lösungen von Oxazaphosphorinen mit verbesserter Stabilität und Verfahren zu deren Herstellung |
| DE3804686A1 (de) * | 1988-02-15 | 1989-08-24 | Henkel Kgaa | Arzneimittel mit einer kombination von cytostatika bzw. hormontherapeutika und phosphonoderivaten |
-
1991
- 1991-07-15 RO RO148008A patent/RO113611B1/ro unknown
- 1991-07-24 DE DE4124481A patent/DE4124481A1/de not_active Withdrawn
- 1991-07-24 DK DK91112368.5T patent/DK0469440T3/da active
- 1991-07-24 AT AT91112368T patent/ATE110261T1/de not_active IP Right Cessation
- 1991-07-24 EP EP91112368A patent/EP0469440B1/de not_active Expired - Lifetime
- 1991-07-24 MC MC912206A patent/MC2274A1/xx unknown
- 1991-07-24 US US07/733,756 patent/US5158776A/en not_active Expired - Lifetime
- 1991-07-24 ES ES91112368T patent/ES2058999T3/es not_active Expired - Lifetime
- 1991-07-24 DE DE59102620T patent/DE59102620D1/de not_active Expired - Fee Related
- 1991-07-30 MX MX9100441A patent/MX9100441A/es unknown
- 1991-07-31 JP JP3191414A patent/JP3061898B2/ja not_active Expired - Fee Related
- 1991-08-01 EG EG46991A patent/EG19690A/xx active
- 1991-08-01 BG BG94934A patent/BG60900B1/bg unknown
- 1991-08-01 IL IL9903191A patent/IL99031A/en not_active IP Right Cessation
- 1991-08-01 NZ NZ239222A patent/NZ239222A/xx not_active IP Right Cessation
- 1991-08-01 SI SI9111342A patent/SI9111342B/sl not_active IP Right Cessation
- 1991-08-01 PT PT98532A patent/PT98532B/pt not_active IP Right Cessation
- 1991-08-02 CA CA002048367A patent/CA2048367C/en not_active Expired - Lifetime
- 1991-08-02 NO NO913019A patent/NO178252C/no not_active IP Right Cessation
- 1991-08-02 ZA ZA916124A patent/ZA916124B/xx unknown
- 1991-08-02 SK SK2409-91A patent/SK279740B6/sk not_active IP Right Cessation
- 1991-08-02 FI FI913710A patent/FI97951C/fi active
- 1991-08-02 KR KR1019910013365A patent/KR0177170B1/ko not_active Expired - Fee Related
- 1991-08-02 IE IE277491A patent/IE66378B1/en not_active IP Right Cessation
- 1991-08-02 AU AU81589/91A patent/AU643309B2/en not_active Ceased
- 1991-08-02 CN CN91105271A patent/CN1046851C/zh not_active Expired - Fee Related
- 1991-08-02 HU HU912594A patent/HU206268B/hu not_active IP Right Cessation
- 1991-08-02 CZ CS912409A patent/CZ280475B6/cs not_active IP Right Cessation
- 1991-08-02 AR AR91320329A patent/AR247484A1/es active
-
1992
- 1992-09-29 HR HRP-1342/91A patent/HRP920575B1/xx not_active IP Right Cessation
- 1992-10-27 LV LVP-92-172A patent/LV10043B/lv unknown
-
1993
- 1993-08-23 AU AU44836/93A patent/AU649184B2/en not_active Ceased
- 1993-09-03 LT LTIP921A patent/LT3528B/lt not_active IP Right Cessation
-
1994
- 1994-12-30 SG SG181694A patent/SG181694G/en unknown
-
1995
- 1995-02-06 HK HK15695A patent/HK15695A/xx not_active IP Right Cessation
-
1998
- 1998-04-27 SK SK543-98A patent/SK279739B6/sk not_active IP Right Cessation
-
2000
- 2000-01-14 JP JP2000006836A patent/JP3545300B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4443428A (en) | Extended action controlled release compositions | |
| US5047246A (en) | Direct compression cyclophosphamide tablet | |
| CZ2000787A3 (cs) | Farmaceutický prostředek, způsob jeho výroby a použití | |
| SK282277B6 (sk) | Tableta alebo kapsula na prehĺtanie a spôsob jej výroby | |
| CN109793715B (zh) | 一种阿哌沙班口服固体制剂及其制备方法 | |
| JPH09504015A (ja) | 活性物質を迅速に又は制御された態様で放出する非常に効果的なスルホニル尿素製剤及びそれらの製造方法 | |
| SK279740B6 (sk) | Spôsob výroby | |
| CZ287984B6 (cs) | Tableta se zlepšenou biodostupností účinné látky, kyseliny klodronové, a způsob její výroby | |
| CS247190B2 (en) | Method of agent with porous matrix production on polycaprolactam base | |
| US20210401748A1 (en) | Powder for oral suspension containing lamotrigine | |
| DE69733752T2 (de) | Arzneimittel enthaltend oxaprozin-natriumsalz,-kaliumsalz, oder-tris(hydroxymethyl)aminomethansalz | |
| JPH1192369A (ja) | 医薬品調製物、その製造方法及びシランセトロンの安定化のための酸性添加剤の使用 | |
| JP2002532429A (ja) | 薬学的処方物 | |
| RU2039553C1 (ru) | Твердая лекарственная форма ифосфамида | |
| US20080081069A1 (en) | Novel controlled release formulations of divalproex sodium | |
| EP0973508A1 (en) | Pharmaceutical tablet of amiodarone salt | |
| SK11072000A3 (sk) | Tiagabínové prostriedky s predĺženým uvoľňovaním so zníženými vedľajšími účinkami | |
| WO2025110967A1 (en) | A modified release tablet composition of brivaracetam | |
| GB2639602A (en) | An orodispersible tablet of pregabalin and its process of preparation | |
| RU2266106C1 (ru) | Способ получения антимикробного средства | |
| CZ20002675A3 (cs) | Tiagabinové prostředky s prodlouženým uvolňováním se sníženými vedlejšími účinky |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed due to non-payment of maintenance fees |
Effective date: 20100802 |